IOL Chemicals & Pharmaceuticals Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/de1i7j2ilx78twylmq3iuyle.pdf

Key Takeaways


Performance & Segment Dynamics

Khanna: "In respect to EBITDA margin, we are not able to achieve the target because of unexpected rise in the fuel cost. So now we hope we will do better in the coming quarter."

Revenue Mix & Strategic Targets

Singh: "The ideal we are thinking is 25% and 75%. So 25% from the chemical and 75% from the API. And between these APIs, the near-term objective of ours is to divide it into the 50-50."

Margin Trajectory & Cost Realities

Singh: "Initially we said that we will try to reach to around 14% to 15%, after that we said we will be reaching to around 13%. But I think now we are just understanding that we will be reaching something 11% to 12%."

Growth Drivers & Pipeline


Capital Allocation & Competitive Positioning


Guidance & Commitments

CommitmentSpecificsTimeline
Q4 EBITDA margin improvementIncrease by 1–2% from Q3 levels; recover INR2–3 crores missQ4 FY26
FY27 revenue growthMinimum 10–15% top-line growthFY27
FY27 bottom-line growth15–20% growthFY27
FY27 capexINR150–200 crores, 60:40 growth vs infra/automation splitFY27
Revenue mix60% API, 40% chemicalWithin 2 years
API sub-mix50% ibuprofen, 50% non-ibuprofenNear-term (undated)
Minoxidil API commercializationFinal API for regulated international marketsQ1 FY27
FY27 revenue targetINR2,700 crores (INR1,800 cr API, INR900 cr chemical)FY27

Key Metrics

MetricQ3 FY26
Revenue from operations₹580 cr, +10.9% YoY
EBITDA₹62.6 cr, +22.8% YoY
EBITDA margin10.7%, up from 9.7% YoY
PBT before exceptional items₹38.8 cr, +39.3% YoY
PBT margin6.6%, up from 5.3% YoY
Exceptional item₹11.2 cr, provision for new labour law, non-recurring
9M FY26 revenue₹1,699.6 cr, +9.6% YoY
9M FY26 EBITDA margin11.4%, up from 10% YoY
Pharma segment revenue₹356 cr, 61% of total revenue
Chemical segment revenue₹224 cr, 39% of total revenue
Ibuprofen API revenue₹228 cr, 64% of pharma revenue
Non-ibuprofen API revenue₹128 cr, 36% of pharma revenue, up from 34% YoY
Ibuprofen capacity utilisation90–95%
Chemicals capacity utilisationnear 200%
Paracetamol capacity utilisation~60%, expansion underway
FY27 revenue target₹2,700 cr, with ₹1,800 cr from API and ₹900 cr from chemicals
FY27 top-line growth guidance10–15% minimum
FY27 bottom-line growth guidance15–20%
Q4 FY26 revenue expectation₹600 cr
Q4 FY26 EBITDA margin expectation~11%, slightly better than Q3
FY26 capex₹130–135 cr, 60% growth, 40% infra and automation
Total inventory~₹350 cr